JPMorgan Chase & Co. Raises Stake in Charles River Laboratories International, Inc. $CRL

Key Points

• JPMorgan Chase & Co. boosted its stake in Charles River by 14.5% in Q3 to 317,179 shares (about $49.6 million), equal to roughly 0.64% ownership.
• Charles River slightly beat estimates with EPS of $2.39 (vs. $2.33) and revenue of $994.2M, but reported a negative net margin (-3.59%) and set FY2026 guidance of 10.70–11.20 EPS.
• Analysts hold a consensus “Moderate Buy” with an average price target of $206.15, while the stock trades near $153.52, has a market cap of $7.56B and a trailing P/E of -51.86.

JPMorgan Chase & Co. boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 14.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 317,179 shares of the medical research company's stock after buying an additional 40,073 shares during the quarter. JPMorgan Chase & Co. owned 0.64% of Charles River Laboratories International worth $49,626,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Jones Financial Companies Lllp raised its holdings in shares of Charles River Laboratories International by 167.6% during the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock worth $253,000 after purchasing an additional 1,074 shares during the last quarter. Empowered Funds LLC purchased a new stake in Charles River Laboratories International in the first quarter valued at $418,000. Allworth Financial LP boosted its holdings in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company's stock valued at $45,000 after purchasing an additional 190 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Charles River Laboratories International by 3.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,046 shares of the medical research company's stock worth $1,828,000 after purchasing an additional 352 shares during the period. Finally, Creative Planning grew its position in Charles River Laboratories International by 7.1% during the 2nd quarter. Creative Planning now owns 8,894 shares of the medical research company's stock worth $1,349,000 after purchasing an additional 586 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Up 0.3%

Shares of NYSE CRL opened at $153.52 on Friday. The firm has a market cap of $7.56 billion, a price-to-earnings ratio of -51.86, a price-to-earnings-growth ratio of 2.62 and a beta of 1.64. The company's 50-day simple moving average is $185.42 and its 200-day simple moving average is $180.56. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same quarter in the prior year, the firm earned $2.66 EPS. The company's revenue for the quarter was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of several analyst reports. Mizuho decreased their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a report on Friday, February 20th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. TD Cowen reduced their price target on Charles River Laboratories International from $251.00 to $235.00 and set a "buy" rating for the company in a research report on Friday, February 20th. Robert W. Baird set a $193.00 price target on Charles River Laboratories International in a report on Thursday, February 19th. Finally, Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a research note on Monday, December 1st. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $206.15.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.